BioSpace News Archive

Fate Therapeutics, Inc. presented interim clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT819 for patients with relapsed / refractory B-cell lymphoma at the 64th American Society of Hematology Annual Meeting and Exposition.

Orum Therapeutics announced the presentation of positive preclinical data for ORM-6151, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for acute myeloid leukemia, at the 64th American Society of Hematology Annual Meeting & Exposition taking place December 10-13 in New Orleans and virtually.

Global biotechnology leader CSL announced the presentation of data affirming the long-term durability and safety of single-infusion HEMGENIX® in the treatment of certain adults living with hemophilia B at the 64th American Society of Hematology Annual Meeting.

Precision BioSciences, a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, presented a novel, product-attributes analysis of its lead CD19 allogeneic CAR T candidate, Azercabtagene Zapreleucel that shows a relationship between CAR T cell composition and effective cell dose with pharmacokinetics, pharmacodynamics, and clinical outcomes.

Sutro Biopharma, Inc. announced that its research collaborators at Fred Hutchinson Cancer Research Center presented data from the Compassionate Use Program on anti-leukemic activity of STRO-002 in pediatric patients with relapsed/refractory CBFA2T3-GLIS2 acute myeloid leukemia, commonly known as RAM phenotype AML, in an oral presentation at the 64th ASH Annual Meeting and Exposition in New Orleans, LA.

LAVA Therapeutics N.V. announced a poster presentation highlighting updated data, including safety, pharmacodynamics and pharmacokinetics from the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsing/refractory chronic lymphocytic leukemia and multiple myeloma at the 64th American Society of Hematology Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10–13, 2022.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced initial safety and efficacy findings from dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine in combination with Vidaza® and Venclexta® in patients with relapsed/refractory and frontline acute myeloid leukemia.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new four-year follow-up results from the Phase 3 GLOW study, which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia compared to patients treated with chemoimmunotherapy.

AbbVie announced new and updated data across clinical and real-world studies in chronic lymphocytic leukemia.